FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013148180> ?p ?o ?g. }

• W2013148180 endingPage "423" @default.
• W2013148180 startingPage "416" @default.
• W2013148180 abstract "Combined modality therapy has become the treatment of choice for patients with primary breast cancer, including those with locally advanced breast cancer. Primary or induction chemotherapy, followed by surgery or radiation therapy or both, and adjuvant systemic therapy is a generally accepted strategy. Most tumors respond with a more than 50% decrease in tumor size, and approximately 70% of patients experience down-staging through primary chemotherapy. Breast conservation is possible for many patients with locally advanced breast cancer, and almost all patients initially are rendered disease free. Primary chemotherapy should be the initial choice of treatment for patients with locally advanced tumors, but it is unclear what the optimal sequence of subsequent therapies should be, or whether one or two local treatment modalities are necessary. The most dramatic example of the efficacy of these regimens was demonstrated in patients with inflammatory breast cancer. Previously a universally fatal condition, the natural history of this disease has been changed dramatically by the introduction of these combined modality therapies. Five-year survival rates of 35–60% commonly are reported, and it is likely that about one third of patients with this highly aggressive form of disease will survive beyond 10 years without recurrence. Combined modality therapy that includes primary chemotherapy provides appropriate local control, the possibility of breast conservation therapy, and, probably, an increased survival rate, at least for some subsets of patients with locally advanced breast cancer. The use of similar treatment strategies for early breast cancer is currently under evaluation. Hormone therapy and combination chemotherapy represent the main treatment approaches to metastatic breast cancer. Radiotherapy is also a useful palliative tool, especially for control of painful bone metastases and central nervous system involvement. Patient and tumor characteristics help in the optimal selection of systemic therapy. Palliative therapy for symptomatic control and prolongation of life also preserves a good quality of life. Dose-intensive chemotherapy is being evaluated as a treatment to increase complete response rates and cause remission consolidation. Clinical trials on several new and effective cytotoxic agents, as well as new hormonal compounds, are being completed and are showing encouraging preliminary results. Monoclonal antibodies to specific tumor antigens, growth factors, or their receptors have opened the possibility of more selective and potentially more effective treatments. Clinical investigation during the next decade will establish the role of these new modalities in the overall management of patients with breast cancer." @default.
• W2013148180 created "2016-06-24" @default.
• W2013148180 creator A5018617106 @default.
• W2013148180 date "1994-01-01" @default.
• W2013148180 modified "2023-09-26" @default.
• W2013148180 title "Multidisciplinary management of advanced primary and metastatic breast cancer" @default.
• W2013148180 cites W1198393149 @default.
• W2013148180 cites W1829692437 @default.
• W2013148180 cites W1892756525 @default.
• W2013148180 cites W190417444 @default.
• W2013148180 cites W1913192549 @default.
• W2013148180 cites W1935743463 @default.
• W2013148180 cites W1968468730 @default.
• W2013148180 cites W1970296191 @default.
• W2013148180 cites W1971539939 @default.
• W2013148180 cites W1986339857 @default.
• W2013148180 cites W1988920760 @default.
• W2013148180 cites W1990852233 @default.
• W2013148180 cites W1995671931 @default.
• W2013148180 cites W2002326574 @default.
• W2013148180 cites W2019777932 @default.
• W2013148180 cites W2040896752 @default.
• W2013148180 cites W2041690603 @default.
• W2013148180 cites W2051729426 @default.
• W2013148180 cites W206480088 @default.
• W2013148180 cites W2069853074 @default.
• W2013148180 cites W2073180107 @default.
• W2013148180 cites W2083922824 @default.
• W2013148180 cites W2086766680 @default.
• W2013148180 cites W2092831709 @default.
• W2013148180 cites W2095259252 @default.
• W2013148180 cites W2142864637 @default.
• W2013148180 cites W2147687816 @default.
• W2013148180 cites W2148252918 @default.
• W2013148180 cites W2413055355 @default.
• W2013148180 cites W4255152173 @default.
• W2013148180 doi "https://doi.org/10.1002/cncr.2820741329" @default.
• W2013148180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8004615" @default.
• W2013148180 hasPublicationYear "1994" @default.
• W2013148180 type Work @default.
• W2013148180 sameAs 2013148180 @default.
• W2013148180 citedByCount "116" @default.
• W2013148180 countsByYear W20131481802012 @default.
• W2013148180 countsByYear W20131481802013 @default.
• W2013148180 countsByYear W20131481802014 @default.
• W2013148180 countsByYear W20131481802015 @default.
• W2013148180 countsByYear W20131481802016 @default.
• W2013148180 countsByYear W20131481802017 @default.
• W2013148180 countsByYear W20131481802018 @default.
• W2013148180 countsByYear W20131481802019 @default.
• W2013148180 countsByYear W20131481802020 @default.
• W2013148180 countsByYear W20131481802021 @default.
• W2013148180 countsByYear W20131481802022 @default.
• W2013148180 countsByYear W20131481802023 @default.
• W2013148180 crossrefType "journal-article" @default.
• W2013148180 hasAuthorship W2013148180A5018617106 @default.
• W2013148180 hasBestOaLocation W20131481801 @default.
• W2013148180 hasConcept C121608353 @default.
• W2013148180 hasConcept C126322002 @default.
• W2013148180 hasConcept C141071460 @default.
• W2013148180 hasConcept C143998085 @default.
• W2013148180 hasConcept C163276114 @default.
• W2013148180 hasConcept C2775930923 @default.
• W2013148180 hasConcept C2776694085 @default.
• W2013148180 hasConcept C2778311097 @default.
• W2013148180 hasConcept C2779013556 @default.
• W2013148180 hasConcept C2779134260 @default.
• W2013148180 hasConcept C2780283643 @default.
• W2013148180 hasConcept C509974204 @default.
• W2013148180 hasConcept C530470458 @default.
• W2013148180 hasConcept C71924100 @default.
• W2013148180 hasConceptScore W2013148180C121608353 @default.
• W2013148180 hasConceptScore W2013148180C126322002 @default.
• W2013148180 hasConceptScore W2013148180C141071460 @default.
• W2013148180 hasConceptScore W2013148180C143998085 @default.
• W2013148180 hasConceptScore W2013148180C163276114 @default.
• W2013148180 hasConceptScore W2013148180C2775930923 @default.
• W2013148180 hasConceptScore W2013148180C2776694085 @default.
• W2013148180 hasConceptScore W2013148180C2778311097 @default.
• W2013148180 hasConceptScore W2013148180C2779013556 @default.
• W2013148180 hasConceptScore W2013148180C2779134260 @default.
• W2013148180 hasConceptScore W2013148180C2780283643 @default.
• W2013148180 hasConceptScore W2013148180C509974204 @default.
• W2013148180 hasConceptScore W2013148180C530470458 @default.
• W2013148180 hasConceptScore W2013148180C71924100 @default.
• W2013148180 hasIssue "S1" @default.
• W2013148180 hasLocation W20131481801 @default.
• W2013148180 hasLocation W20131481802 @default.
• W2013148180 hasOpenAccess W2013148180 @default.
• W2013148180 hasPrimaryLocation W20131481801 @default.
• W2013148180 hasRelatedWork W2139647583 @default.
• W2013148180 hasRelatedWork W2201476026 @default.
• W2013148180 hasRelatedWork W2206223252 @default.
• W2013148180 hasRelatedWork W2348231456 @default.
• W2013148180 hasRelatedWork W2367105124 @default.
• W2013148180 hasRelatedWork W2367923615 @default.
• W2013148180 hasRelatedWork W2379151083 @default.
• W2013148180 hasRelatedWork W2388730008 @default.

• next